Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

31.73 -0.59 (-1.84%)
Streaming Delayed Price Updated: 10:37 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Why Are Atea Pharmaceuticals Shares Plunging Today?
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate... 
Via Benzinga
Chinese Growth Level
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops
Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal. 
Via Investor's Business Daily
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
Europe's Unicorns
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
NetworkNewsAudio – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Harnessing Power of Real-World Data
Via Investor Brand Network
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
Exposures COVID-19
New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder
From Genentech
Via Business Wire
New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
Real-World Data, Point-of-Care Testing Reshaping Healthcare, Detecting Diseases Sooner
Via Investor Brand Network
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB... 
Via Talk Markets
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK... 
Via Benzinga
Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
From Genentech
Via Business Wire
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation
Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is... 
Via Benzinga
Exposures Product Safety
Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
From Genentech
Via Business Wire
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
Merck & Co., Inc. (NYSE:MRK) 
Via Benzinga
Exposures COVID-19
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
From Genentech
Via Business Wire
October Starts Positive
A lot of these moves are simply reactions to last month's excesses and they may not be predictive for October at all. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's (NYSE: LH) combined home collection kit to detect COVID-19 and... 
Via Benzinga
Exposures COVID-19 Product Safety
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial
BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial... 
Via Benzinga
September Ends
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling. 
Via Talk Markets
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.